Anti-NKG2D/ KLRK1/ CD314 monoclonal antibody
Anti-NKG2D/ KLRK1/ CD314 antibody for FACS & in-vivo assay
Go to KLRK1/KLRK1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T35289-Ab-1/ GM-Tg-hg-T35289-Ab-2 | Anti-Human KLRK1 monoclonal antibody | Human |
GM-Tg-rg-T35289-Ab-1/ GM-Tg-rg-T35289-Ab-2 | Anti-Rat KLRK1 monoclonal antibody | Rat |
GM-Tg-mg-T35289-Ab-1/ GM-Tg-mg-T35289-Ab-2 | Anti-Mouse KLRK1 monoclonal antibody | Mouse |
GM-Tg-cynog-T35289-Ab-1/ GM-Tg-cynog-T35289-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KLRK1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T35289-Ab-1/ GM-Tg-felg-T35289-Ab-2 | Anti-Feline KLRK1 monoclonal antibody | Feline |
GM-Tg-cang-T35289-Ab-1/ GM-Tg-cang-T35289-Ab-2 | Anti-Canine KLRK1 monoclonal antibody | Canine |
GM-Tg-bovg-T35289-Ab-1/ GM-Tg-bovg-T35289-Ab-2 | Anti-Bovine KLRK1 monoclonal antibody | Bovine |
GM-Tg-equg-T35289-Ab-1/ GM-Tg-equg-T35289-Ab-2 | Anti-Equine KLRK1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T35289-Ab-1/ GM-Tg-hg-T35289-Ab-2; GM-Tg-rg-T35289-Ab-1/ GM-Tg-rg-T35289-Ab-2; GM-Tg-mg-T35289-Ab-1/ GM-Tg-mg-T35289-Ab-2; GM-Tg-cynog-T35289-Ab-1/ GM-Tg-cynog-T35289-Ab-2; GM-Tg-felg-T35289-Ab-1/ GM-Tg-felg-T35289-Ab-2; GM-Tg-cang-T35289-Ab-1/ GM-Tg-cang-T35289-Ab-2; GM-Tg-bovg-T35289-Ab-1/ GM-Tg-bovg-T35289-Ab-2; GM-Tg-equg-T35289-Ab-1/ GM-Tg-equg-T35289-Ab-2 |
Products Name | Anti-KLRK1 monoclonal antibody |
Format | mab |
Target Name | KLRK1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-KLRK1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-566 | Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody |
Target Antigen | Products Developing | Multi-species NKG2D/ KLRK1/ CD314 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP000859 | human KLRK1 Lentivirus plasmid |
ORF Viral Vector | vGMLP000859 | human KLRK1 Lentivirus particle |
ORF Viral Vector | pGMLPm001912 | mouse Klrk1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm001912 | mouse Klrk1 Lentivirus particle |
Target information
Target ID | GM-T35289 |
Target Name | KLRK1 |
Gene ID | 22914,27007,24934,100053963 |
Gene Symbol and Synonyms | CD314,D12S2489E,D6H12S2489E,KLR,KLRK1,NKG2-D,NKG2D,Nkrp2 |
Uniprot Accession | P26718,O70215 |
Uniprot Entry Name | NKG2D_HUMAN,NKG2D_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | Cancer |
Gene Ensembl | ENSG00000213809 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: KLRK1, gene name: KLRK1, also named as CD314, D12S2489E, KLR, NKG2-D, NKG2D. Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins, where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster. [provided by RefSeq, Dec 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.